Y-mAbs Therapeutics, Inc.

NasdaqGS:YMAB Voorraadrapport

Marktkapitalisatie: US$466.3m

Y-mAbs Therapeutics Toekomstige groei

Future criteriumcontroles 1/6

De winst van Y-mAbs Therapeutics zal naar verwachting dalen met 22.8% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 12.3% per jaar. De winst per aandeel zal naar verwachting dalen met 16.6% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -8.6% zijn.

Belangrijke informatie

-22.8%

Groei van de winst

-16.6%

Groei van de winst per aandeel

Biotechs winstgroei28.3%
Inkomstengroei12.3%
Toekomstig rendement op eigen vermogen-8.6%
Dekking van analisten

Good

Laatst bijgewerkt18 Nov 2024

Recente toekomstige groei-updates

Recent updates

The Market Doesn't Like What It Sees From Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Revenues Yet As Shares Tumble 26%

Nov 19
The Market Doesn't Like What It Sees From Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Revenues Yet As Shares Tumble 26%

Y-mAbs Therapeutics: Slow But Steady Prospect In Rare Cancers

Oct 21

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Held Back By Insufficient Growth Even After Shares Climb 33%

Sep 12
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Held Back By Insufficient Growth Even After Shares Climb 33%

Revisiting Y-mAbs After The Summer Oncology Meeting (Rating Upgrade)

Aug 12

We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Jul 15
We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Investors Don't See Light At End Of Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Tunnel And Push Stock Down 29%

Jun 02
Investors Don't See Light At End Of Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Tunnel And Push Stock Down 29%

Y-mAbs: There's A Ceiling Here Somewhere

May 09

We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Mar 14
We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry

Feb 17
Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry

Y-mAbs Therapeutics: A Monoclonal Antibody Play

Jan 14

We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate

Nov 13
We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth

Jul 16
We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth

Party Time: Brokers Just Made Major Increases To Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Earnings Forecasts

May 13
Party Time: Brokers Just Made Major Increases To Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Earnings Forecasts

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Price Is Right But Growth Is Lacking After Shares Rocket 104%

Apr 17
Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Price Is Right But Growth Is Lacking After Shares Rocket 104%

Y-mAbs Therapeutics (NASDAQ:YMAB) Will Have To Spend Its Cash Wisely

Mar 22
Y-mAbs Therapeutics (NASDAQ:YMAB) Will Have To Spend Its Cash Wisely

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Needs To Drive Business Growth Carefully

Dec 13
We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Needs To Drive Business Growth Carefully

Analysts Just Shaved Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Forecasts Dramatically

Aug 13
Analysts Just Shaved Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Forecasts Dramatically

Y-mAbs gets FDA nod to begin phase 1 study of GD2-SADA for certain cancers

Jul 12

Y-mAbs Therapeutics: Steady, Small Steps Targeting Rare Cancers

May 30

Winst- en omzetgroeiprognoses

NasdaqGS:YMAB - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/2026117-46-31-497
12/31/2025108-29-26-2210
12/31/202488-28-24-2410
9/30/202485-24-22-22N/A
6/30/202487-25-13-13N/A
3/31/202484-22-18-18N/A
12/31/202385-21-27-27N/A
9/30/202393-19-28-28N/A
6/30/202385-39-46-46N/A
3/31/202375-74-64-64N/A
12/31/202265-96-76-76N/A
9/30/202243-134-102-101N/A
6/30/202240-135-100-100N/A
3/31/202240-117-96-96N/A
12/31/202135-55-104-103N/A
9/30/202146-38-87-86N/A
6/30/202137-42-93-92N/A
3/31/202126-60-102-101N/A
12/31/202021-119-91-91N/A
9/30/2020N/A-123-99-98N/A
6/30/2020N/A-114-97-95N/A
3/31/2020N/A-91-84-82N/A
12/31/2019N/A-81-75-73N/A
9/30/2019N/A-72-63-62N/A
6/30/2019N/A-59-51-50N/A
3/31/2019N/A-52-48-48N/A
12/31/2018N/A-43-41-41N/A
9/30/2018N/A-38-34-34N/A
6/30/2018N/A-31N/A-27N/A
3/31/2018N/A-24N/A-19N/A
12/31/2017N/A-19N/A-16N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat YMAB de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat YMAB de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat YMAB de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van YMAB ( 12.3% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van YMAB ( 12.3% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat YMAB binnen 3 jaar verliesgevend zal zijn.

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y